Detection and Analysis ofEGFR andKRAS Mutation with Lung Adenocarcinoma
10.3779/j.issn.1009-3419.2015.11.05
- VernacularTitle:肺腺癌EGFR与KRAS基因突变状态分析
- Author:
ZHANG HUI
1
;
YANG XINJIE
;
QIN NA
;
LI XI
;
YANG HUIYI
;
NONG JINGYING
;
LV JIALIN
;
WU YUHUA
;
ZHANG QUAN
;
ZHANG XINYONG
;
WANG JINGHUI
;
ZHOU LIJUAN
;
ZHANG SHUCAI
Author Information
1. 首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所肿瘤内科
- Keywords:
Lung neoplasms;
Epidermal growth factor receptor;
KARS gene;
Mutation;
Adenocarcinoma
- From:
Chinese Journal of Lung Cancer
2015;(11):686-690
- CountryChina
- Language:Chinese
-
Abstract:
Background and objectiveMutations in epidermal growth factor receptor (EGFR) andKARS are im-portant markers in non-small cell lung cancer, which are closely related to the clinical therapeutic effect. To analysis theEGFR andKARS gene mutation rate and its relationship with clinical features in patients with lung adenocarcinoma.Methods395 patients with treatment na?ve lung adenocarcinoma, tumor tissue samples were available for testing. Tumor sampleEGFR and KARS mutation status were detected using mutant enriched liquidchip.Results 395 cases of lung adenocarcinoma,EGFR mutations were detected in 192 cases (48.9%),KARS mutations were detected in 29 cases (7.8%), and the presence ofEGFR andKARS mutation were detected in 1 case (0.3%).EGFR mutations were found to occur signiifcantly more otfen in female than in male patients (62.0%vs 37.1%,P<0.001) and in never smokers than in smokers (61.9%vs 30.3%,P<0.001), no sig-niifcant differences were observed in age, stage and different biopsy type.KARS mutations were not found to have statistical signiifcance (P>0.05) in each clinical factors, only occurred in the wild typeEGFR gene in patients (13.5%, 27/200) was sig-niifcantly higher than that of patients withEGFR mutation (1.0%, 2/192), the difference was statistically signiifcant (P<0.001). ConclusionIn lung adenocarcinomas,EGFR mutation was higher in female and non-smoking patients,KARS mutation only in patients with wild-typeEGFR gene was higher. Before using TKI targeted therapy,EGFR andKARS mutations should be detected.
